Calls
6
#980
Alpha Score 46.4
u/TheAirNearMyFingers
Reddit r/ValueInvesting
Win Rate
83.3%
return
+3.3%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Feb 03
$29.37
+0.3%
Author calls Viking Therapeutics a pure acquisition play because its dual-agonist and oral GLP-1 candidate could be best-in-class, and he expects it could be bought for a similar amount to Metsera's $10B takeover. With Viking's current valuation around $3B, he sees a lot of value and notes NVO should consider acquiring it. Main stated risk is that it is an acquisition play, so if that scares you, move on.
GLP-1 / Obesity
Long
Feb 03
$372.00
+0.6%
Author includes Biocon among generic semaglutide makers that will launch in Canada, Brazil, and India, and says he has held and likes all these generic companies more than NVO. The thesis is that semaglutide patent expirations create a generic opportunity in large markets. Main stated risk is not specific to Biocon, though the space is competitive and the author says Teva has already ripped 70%.
Other
Long
Feb 03
$13.84
-10.8%
Author lists Dr. Reddy's among generic semaglutide makers that will launch in Brazil and India alongside Sandoz, Biocon, and Teva, and he discloses holding RDY. The thesis is that patent expirations for semaglutide open generic opportunities for these companies. No separate risk beyond the generic-space competition is stated.
Pharma & Biotech
Showing 3 of 6 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/TheAirNearMyFingers has 6 trade ideas tracked on Buzzberg across 6 tickers since February 2026. Ranked #980 on the Buzzberg Alpha leaderboard. Most covered: LLY, TEVA, VKTX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
